Australia Regular PharmaBoardroom contributor Brendan Shaw outlines how his home country of Australia has so far successfully managed to avoid the worst of the COVID-19 pandemic, providing opportunities for the life sciences industry to invest in new facilities, research and development in a post-pandemic world. Australia, the island continent A…
Australia In an exclusive new podcast, DIA Global Forum Australia/New Zealand Regional Editor Richard Day (University of New South Wales, Medicine, St. Vincent’s Hospital) and John Skeritt, Head of Australia’s Therapeutic Goods Administration (TGA), discuss regulatory strategies and other initiatives designed to help nurture clinical research and product development in Australia post-pandemic. With…
UK When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to leave the European Union, some analysts feared that Britain could become left behind in terms of alignment with the world’s top regulatory bodies. Perhaps cognizant of this, the UK regulatory agency for…
Opinion Janssen Australia & New Zealand’s Bruce Goodwin argues that greater adoption of patient-centric practices is beneficial to patients, companies and healthcare systems as a whole. Goodwin also gives his five fundamental pillars to adopting a patient-centric approach. We know that patient-centricity not only aids better healthcare, it also has…
Phebra Australia Can you start by giving our readers a brief overview of the company’s history here and your most notable achievements? Initially the company was founded as a small distributor of relatively specialized pharmaceutical products. Over the years we saw a growing demand for these special, difficult to manufacture drugs or…
Australia Would you begin by outlining the role & importance of George Clinical within the George Institute, highlighting recent milestones & achievements? George Clinical is an important division of the Institute, contributing to its research goals in several ways: We provide operations teams to deliver clinical trials i.e. the (usually) randomized,…
Australia Would you begin by giving an introduction to our international readers of the institute, highlighting recent milestones & achievements and the current focus areas of its research activities? Broadly speaking, The George Institute for Global Health is an academic research organization that focuses on high impact clinical research. We do…
Celgene Australia In our interviews we have been hearing two opinions on the success of PBS reforms: that it works as it should in providing space for innovative medicine listings, and that the number of listings has decreased to a point where Australia is in danger of losing its attractiveness as an…
Celgene Australia “Australia is not just a postbox for selling drugs; Celgene is committed to establishing a major presence in the region,” you said when Focus Reports met you first in 2008. Since then, what have been the highlights in the Celgene development in this part of the world? When Celgene decided…
Dr Reddy's Laboratories Australia Dr. Reddy’s entered Australia under your leadership. Would you outline the key milestones & achievements? Our first product was available to us for commercialization in Jan 2010 and since then we have grown rapidly on several parameters , about 1000 community pharmacies buy Dr.Reddy’s products directly , we also work…
Array After just six months in the country, Novartis Australia’s new Managing Director offers his perspectives on the Australian pharmaceutical market and healthcare system, his company’s commitment to R&D, and Australia’s competitiveness for clinical trials in the Asian context. You arrived in July 2012 after working in different positions for…
See our Cookie Privacy Policy Here
